Kinetics of the inflammatory response induced by free fatty acid accumulation in hepatocytes

Annals of Hepatology

Volumn 13, Issue 1, 2014, Pages 113-120

  Chávez Tapia, Norberto C ^a,b,c   Rosso, Natalia ^a   Uribe, Misael ^b   Bojalil, Rafel ^d,e   Tiribelli, Claudio ^a,f  

^a Centro Studi Fegato   (Italy)

^b UNIVERSIDAD AUTÓNOMA METROPOLITANA   (Mexico)

^c LIVER RESEARCH UNIT   (Mexico)

^d DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

^e INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^f UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Fatty liver; Liver; Molecular biology

Indexed keywords

FAT DROPLET; FATTY ACID; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; OLEIC ACID; PALMITIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL KINETICS; CELL VIABILITY; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOTOXICITY; FAT CONTENT; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HUMAN; HUMAN CELL; IL 6 GENE; IL 8 GENE; IN VITRO STUDY; INFLAMMATION; LIPID STORAGE; LIPOTOXICITY; LIVER CELL; NONALCOHOLIC FATTY LIVER; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; TNF ALPHA GENE; TOXICITY TESTING; UPREGULATION;

CELL LINE; CELL SURVIVAL; CYTOKINES; FATTY ACIDS, NONESTERIFIED; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; OLEIC ACID; PALMITIC ACID; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893651123     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)30912-3     Document Type: Article

References (42)

1. Lizardi-Cervera J, Laparra DI, Chavez-Tapia NC, Ostos ME, Esquivel MU. Prevalence of NAFLD and metabolic syndrome in asymtomatics subjects. Rev Gastroenterol Mex 2006; 71: 453-9.
2. Roesch-Dietlen F, Dorantes-Cuellar A, Carrillo-Toledo MG, Martinez-Sibaja C, Rojas-Carrera S, Bonilla-Rojas QC, Uchino-Higueras V, et al. Frequency of NAFLD in a group of patients with metabolic syndrome in Veracruz, Mexico. Rev Gastroenterol Mex 2006; 71: 446-52.
3. Ramos Medina A, Remes-Troche JM, Roesch-Dietlen FB, Perez-Morales AG, Martinez S, Cid-Juarez S. Routine liver biopsy to screen for nonalcoholic fatty liver disease (NAFLD) during cholecystectomy for gallstone disease: is it justified? J Gastrointest Surg 2008; 12: 2097-2102; discussion 2102.
4. Carrion AF, Ghanta R, Carrasquillo O, Martin P. Chronic liver disease in the Hispanic population of the United States. Clin Gastroenterol Hepatol 2011; 9: 834-841; quiz e109-e810.
5. Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, Unalp-Arida A, et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012; 55: 769-80.
6. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-31.
7. Mendez-Sanchez N, Villa AR, Chavez-Tapia NC, Ponciano Rodriguez G, Almeda-Valdes P, Gonzalez D, Uribe M. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005; 4: 52-5.
8. Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Perez-Ayuso RM, Gonzalez R, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int 2009; 29: 82-8.
9. Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes care 2012; 35: 717-22.
10. Martel C, Esposti DD, Bouchet A, Brenner C, Lemoine A. Non-alcoholic steatohepatitis: new insights from OMICS studies. Current pharmaceutical biotechnology 2012; 13: 726-35.
11. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93: S57-S63.
12. Bassols J, Ortega FJ, Moreno-Navarrete JM, Peral B, Ricart W, Fernandez-Real JM. Study of the proinflammatory role of human differentiated omental adipocytes. J Cell Biochem 2009.
13. Starr ME, Evers BM, Saito H. Age-associated increase in cytokine production during systemic inflammation: adipose tissue as a major source of IL-6. J Gerontol A Biol Sci Med Sci 2009; 64: 723-30.
14. Nunez NP, Hursting SD, Yakar S, Fowler D, Vinson C. Obesity provides a permissive milieu in inflammation-associated carcinogenesis: analysis of insulin and IGF pathways. Methods Mol Biol 2009; 512: 29-37.
15. Dyck DJ. Adipokines as regulators of muscle metabolism and insulin sensitivity. Appl Physiol Nutr Metab 2009; 34
16. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A 1994; 91: 10878-82.
17. Kakuma T, Lee Y, Higa M, Wang Z, Pan W, Shimomura I, Unger RH. Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Acad Sci U S A 2000; 97: 8536-41.
18. Girard J, Lafontan M. Impact of visceral adipose tissue on liver metabolism and insulin resistance. Part II: Visceral adipose tissue production and liver metabolism. Diabetes Metab 2008; 34: 439-45.
19. Malhi H, Bronk SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 2006; 281: 12093-101.
20. Pusl T, Wild N, Vennegeerts T, Wimmer R, Goke B, Brand S, Rust C. Free fatty acids sensitize hepatocytes to bile acid-induced apoptosis. Biochem Biophys Res Commun 2008; 371: 441-5.
21. Joshi-Barve S, Barve SS, Amancherla K, Gobejishvili L, Hill D, Cave M, Hote P, et al. Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 2007; 46: 823-30.
22. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. WJ Gastroenterol: WJG 2012; 18: 727-35.
23. Chavez-Tapia NC, Rosso N, Tiribelli C. Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterol 2012; 12: 20.
24. Nguyen TH, Mai G, Villiger P, Oberholzer J, Salmon P, Morel P, Buhler L, et al. Treatment of acetaminophen-induced acute liver failure in the mouse with conditionally immortalized human hepatocytes. J Hepatol 2005; 43: 1031-7.
25. Chavez-Tapia NC, Rosso N, Tiribelli C. In vitro models for the study of non-alcoholic fatty liver disease. Current Medicinal Chemistry 2011; 18: 1079-84.
26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
27. McMillian MK, Grant ER, Zhong Z, Parker JB, Li L, Zivin RA, Burczynski ME, et al. Nile Red binding to HepG2 cells: an improved assay for in vitro studies of hepatosteatosis. In Vitr Mol Toxicol 2001; 14: 177-90.
28. Greenspan P, Fowler SD. Spectrofluorometric studies of the lipid probe, nile red. J Lipid Res 1985; 26: 781-9.
29. Sottile V, Seuwen K. Bone morphogenetic protein-2 stimulates adipogenic differentiation of mesenchymal precursor cells in synergy with BRL 49653 (rosiglitazone). FEBS Lett 2000; 475: 201-4.
30. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-35.
31. Tiesset H, Pierre M, Desseyn JL, Guery B, Beermann C, Galabert C, Gottrand F, et al. Dietary (n-3) polyunsaturated fatty acids affect the kinetics of proand antiinflammatory responses in mice with Pseudomonas aeruginosa lung infection. J Nutrition 2009; 139: 82-9.
32. Lehrke M, Broedl UC, Biller-Friedmann IM, Vogeser M, Henschel V, Nassau K, Goke B, et al. Serum concentrations of cortisol, interleukin 6, leptin and adiponectin predict stress induced insulin resistance in acute inflammatory reactions. Critical Care 2008; 12: R157.
33. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273-82.
34. Behnes M, Brueckmann M, Lang S, Putensen C, Saur J, Borggrefe M, Hoffmann U. Alterations of leptin in the course of inflammation and severe sepsis. BMC infectious diseases 2012; 12: 217.
35. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-46.
36. Lentz EK, Leyva-Illades D, Lee MS, Cherla RP, Tesh VL. Differential response of the human renal proximal tubular epithelial cell line HK-2 to Shiga toxin types 1 and 2. Infection and immunity 2011; 79: 3527-40.
37. Temming P, Troger B, Thonnissen S, Holterhus PM, Schultz C, Hartel C. The effect of hyperglycemia on neonatal immune responses in-vitro. J Matern Fetal Neonatal Med 2012; 25: 94-98.
38. Teles M, Mackenzie S, Boltana S, Callol A, Tort L. Gene expression and TNF-alpha secretion profile in rainbow trout macrophages following exposures to copper and bacterial lipopolysaccharide. Fish & shellfish immunology 2011; 30: 340-6.
39. Suganami T, Tanaka M, Ogawa Y. Adipose tissue inflammation and ectopic lipid accumulation. Endocrine J 2012; 59: 849-57.
40. Igoillo-Esteve M, Marselli L, Cunha DA, Ladriere L, Ortis F, Grieco FA, Dotta F, et al. Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. Diabetologia 2010; 53: 1395-405.
41. Krogmann A, Staiger K, Haas C, Gommer N, Peter A, Heni M, Machicao F, et al. Inflammatory response of human coronary artery endothelial cells to saturated long-chain fatty acids. Microvascular Research 2011; 81: 52-9.
42. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Seminars in liver disease 2008; 28: 360-9.